Olorinab

Cannabis Testing Services Market by Test Type, Product Type, End-users, and Region - Global Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 17, 2022

The "Cannabis Testing Services Market, by Test Type, by Product Type, by End-users, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cannabis Testing Services Market, by Test Type, by Product Type, by End-users, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • Increasing adoption of inorganic growth strategies such as acquisition by key players is expected to drive the market growth over the forecast period.
  • For instance, in December 2021, Pfizer Inc., multinational pharmaceutical and Biotechnology Corporation had acquired with the clinical-stage company Arena Pharmaceuticals, a Biotech Company.
  • Furthermore, Pfizer Inc., an American multinational pharmaceutical and biotechnology corporation had signed agreement for testing analysis with the clinical-stage company Arena Pharmaceuticals for a total equity value of around $6.7 billion.

Arena Pharmaceuticals Reports Topline Results from Phase 2b CAPTIVATE Clinical Trial

Retrieved on: 
Tuesday, March 2, 2021

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced topline results from the randomized, double-blind, placebo-controlled Phase 2b CAPTIVATE clinical trial evaluating three doses of olorinab, a novel, oral, peripherally acting, highly selective, full agonist of the cannabinoid receptor 2 (CB2), in participants with abdominal pain due to Irritable Bowel Syndrome (IBS).

Key Points: 
  • Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced topline results from the randomized, double-blind, placebo-controlled Phase 2b CAPTIVATE clinical trial evaluating three doses of olorinab, a novel, oral, peripherally acting, highly selective, full agonist of the cannabinoid receptor 2 (CB2), in participants with abdominal pain due to Irritable Bowel Syndrome (IBS).
  • The CAPTIVATE trial randomized a total of 273 participants and was conducted in study sites across the United States.
  • We want to thank the participants, clinicians, site staff, and the Arena team who participated in this important trial.
  • CAPTIVATE is a Phase 2b, multi-center, randomized, double-blind, placebo-controlled, 12-week study of olorinab in 273 study participants with irritable bowel syndrome (IBS) experiencing abdominal pain.

Arena Pharmaceuticals Presented New Patient-Reported Outcomes Data for Olorinab at the European Society of Neurogastroenterology & Motility NeuroGASTRO 2019 Meeting

Retrieved on: 
Monday, September 9, 2019

SAN DIEGO, Sept. 9, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) presented new patient-reported outcomes data for olorinab, an investigational, oral, peripherally acting, highly-selective, full agonist of the cannabinoid receptor 2 (CB2) in development for the treatment of visceral pain associated with gastrointestinal (GI) disorders, at the European Society of Neurogastroenterology & Motility (ESNM) 2019 NeuroGASTRO Meeting .

Key Points: 
  • SAN DIEGO, Sept. 9, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) presented new patient-reported outcomes data for olorinab, an investigational, oral, peripherally acting, highly-selective, full agonist of the cannabinoid receptor 2 (CB2) in development for the treatment of visceral pain associated with gastrointestinal (GI) disorders, at the European Society of Neurogastroenterology & Motility (ESNM) 2019 NeuroGASTRO Meeting .
  • "We were pleased to see that overall, patient-reported outcomes across all domains evaluated improved at 8 weeks compared to baseline in our Phase 2a study of olorinab.
  • "We look forward to seeing additional data from our Phase 2b CAPTIVATE trial which we expect to read out in the second half of 2020."
  • Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Arena Reports Second Quarter Financial Results with Strong Liquidity Position, and Initiation of Etrasimod ELEVATE UC 52 and Olorinab CAPTIVATE Trials

Retrieved on: 
Wednesday, August 7, 2019

"Arena is off to a strong 2019 and we remain highly focused on achieving several key clinical and regulatory goals.

Key Points: 
  • "Arena is off to a strong 2019 and we remain highly focused on achieving several key clinical and regulatory goals.
  • We are excited to have recently initiated two important trials, the etrasimod Phase 3 ELEVATE UC 52 trial and the olorinab Phase 2 CAPTIVATE trial.
  • We will provide further detail around the CAPTIVATE trial on today's call," said Amit D. Munshi, President and CEO of Arena.
  • "Execution is key for Arena this year, following several positive data readouts and strategic transactions across our pipeline.

Arena Pharmaceuticals Announces First Subject Dosed in CAPTIVATE Phase 2 Trial Evaluating Olorinab in Abdominal Pain Associated with Irritable Bowel Syndrome

Retrieved on: 
Thursday, July 25, 2019

"The majority of IBS patients describe their most problematic symptom as frequent abdominal pain, which often significantly impacts their quality of life.

Key Points: 
  • "The majority of IBS patients describe their most problematic symptom as frequent abdominal pain, which often significantly impacts their quality of life.
  • CAPTIVATE is a Phase 2, multi-center, randomized, double-blind, placebo-controlled, 12-week study of olorinab in patients with irritable bowel syndrome (IBS), experiencing abdominal pain.
  • The primary objective of this trial is to assess the safety and efficacy of olorinab administered three times daily (TID).
  • Arena is also evaluating olorinab (APD371) in a Phase 2 program for gastrointestinal pain.

Analysis on the 2019 Irritable Bowel Syndrome (IBS) Market in the U.S.

Retrieved on: 
Friday, July 12, 2019

DUBLIN, July 12, 2019 /PRNewswire/ -- The "US Irritable Bowel Syndrome Market and Competitive Landscape - 2019" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, July 12, 2019 /PRNewswire/ -- The "US Irritable Bowel Syndrome Market and Competitive Landscape - 2019" report has been added to ResearchAndMarkets.com's offering.
  • US Irritable Bowel Syndrome Market and Competitive Landscape Highlights - 2019,
    provides comprehensive insights into Irritable Bowel Syndrome pipeline products, Irritable Bowel Syndrome epidemiology, Irritable Bowel Syndrome market valuations and forecast, Irritable Bowel Syndrome drugs sales and competitive landscape in the US.
  • Irritable Bowel Syndrome pipeline: Find out the products in clinical trials for the treatment of Irritable Bowel Syndrome by development phase 3, phase 2, and phase 1, by pharmacological class and companies developing the products
    Irritable Bowel Syndrome drugs: Identify key products marketed and prescribed for Irritable Bowel Syndrome in the US, including trade name, molecule name, and company
    Irritable Bowel Syndrome drugs sales: Find out the sales revenues of Irritable Bowel Syndrome drugs in the US
    Irritable Bowel Syndrome market valuations: Find out the market size for Irritable Bowel Syndrome drugs in 2018 in the US.
  • Find out how the market advanced from 2014 and forecast to 2024
    Irritable Bowel Syndrome drugs market share: Find out the market shares for key Irritable Bowel Syndrome drugs in the US
    Evaluate commercial market opportunity assessment, positioning, and segmentation for Irritable Bowel Syndrome products
    1.

The United States Irritable Bowel Syndrome (IBS) Market and Competitive Landscape (2014-2024) - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 11, 2019

The "US Irritable Bowel Syndrome Market and Competitive Landscape - 2019" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "US Irritable Bowel Syndrome Market and Competitive Landscape - 2019" report has been added to ResearchAndMarkets.com's offering.
  • US Irritable Bowel Syndrome Market and Competitive Landscape Highlights - 2019, provides comprehensive insights into Irritable Bowel Syndrome pipeline products, Irritable Bowel Syndrome epidemiology, Irritable Bowel Syndrome market valuations and forecast, Irritable Bowel Syndrome drugs sales and competitive landscape in the US.
  • Irritable Bowel Syndrome pipeline: Find out the products in clinical trials for the treatment of Irritable Bowel Syndrome by development phase 3, phase 2, and phase 1, by pharmacological class and companies developing the products
    Irritable Bowel Syndrome drugs: Identify key products marketed and prescribed for Irritable Bowel Syndrome in the US, including trade name, molecule name, and company
    Irritable Bowel Syndrome drugs sales: Find out the sales revenues of Irritable Bowel Syndrome drugs in the US
    Irritable Bowel Syndrome market valuations: Find out the market size for Irritable Bowel Syndrome drugs in 2018 in the US.
  • Find out how the market advanced from 2014 and forecast to 2024
    Irritable Bowel Syndrome drugs market share: Find out the market shares for key Irritable Bowel Syndrome drugs in the US
    Evaluate commercial market opportunity assessment, positioning, and segmentation for Irritable Bowel Syndrome products
    1.

Constipation-Predominant Irritable Bowel Syndrome Clinical Trial Pipeline Highlights, 2019 - ResearchAndMarkets.com

Retrieved on: 
Friday, June 14, 2019

The "Global Constipation-Predominant Irritable Bowel Syndrome Clinical Trial Pipeline Highlights - 2019" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Constipation-Predominant Irritable Bowel Syndrome Clinical Trial Pipeline Highlights - 2019" report has been added to ResearchAndMarkets.com's offering.
  • Constipation-Predominant Irritable Bowel Syndrome Pipeline Highlights - 2019, provides most up-to-date information on key pipeline products in the global Constipation-Predominant Irritable Bowel Syndrome market.
  • It covers emerging therapies for Constipation-Predominant Irritable Bowel Syndrome in active clinical development stages including early and late stage clinical trials.
  • The report provides Constipation-Predominant Irritable Bowel Syndrome pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Irritable Bowel Syndrome (IBS) Clinical Trial Pipeline Highlights 2019 - Global Forecast to 2024 by Clinical Trial Stages, Drug Mechanism Classes, Company - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 13, 2019

The "Global Irritable Bowel Syndrome Clinical Trial Pipeline Highlights - 2019" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Irritable Bowel Syndrome Clinical Trial Pipeline Highlights - 2019" report has been added to ResearchAndMarkets.com's offering.
  • Irritable Bowel Syndrome Pipeline Highlights - 2019 provides the most up-to-date information on key pipeline products in the global Irritable Bowel Syndrome market.
  • It covers emerging therapies for Irritable Bowel Syndrome in active clinical development stages including early and late stage clinical trials.
  • The report provides Irritable Bowel Syndrome pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.